top of page

Impact Stories

Quantum Quotients: Charting a course for prosperity in lives, resource allocation, and health economics through data constellations. See how we are building healthier communities and creating resilient realities for our clients.

Accounting for 30-50% of maternal mortality in sub-Saharan Africa, postpartum hemorrhage casts a shadow over the region. Regrettably, the under-5 mortality rate stands at 1 death for every 13 live births. Impassioned to improve outcomes, a dedicated team led by Dr. Dickens Onyango, a Medical Doctor and Public Health Researcher in Kisumu County, Kenya, recruited Quantiva Health to collaboratively embark on a transformative mission to make a difference.

Birthing Hope: Transformative Initiatives for Maternal and Infant Well-being in Sub-Saharan Africa

"Since 2021 my team has had a transformative partnership with Quantiva Health, generously funded by the Bill & Melinda Gates Foundation. Together, we harnessed the power of MIHIC models to retrospectively analyze and prospectively predict propensity for critical outcomes like postpartum hemorrhage, preterm birth, and unplanned C-sections in maternal health populations from 25 primary health facilities in Kisumu County.

Our collaborative efforts, highlighted in our joint publication in Frontiers, proudly showcase predictive metrics reaching an impressive 95% accuracy. The journey with CognitiveCare has been nothing short of groundbreaking, shaping a brighter future for healthcare in low-resource settings in particular.”

 

- Dr. Dickens Onyango, MBChB, MSc, and PhD

Quantiva Health’s patented MIHIC Score® solution is empowering public health departments, providers, and other healthcare stakeholders to identify risk at individual and population levels – ensuring optimized outcomes, hyper-personalized care, and effective resource allocation.

Accounting for 30-50% of maternal mortality in sub-Saharan Africa, postpartum hemorrhage casts a shadow over the region. Regrettably, the under-5 mortality rate stands at 1 death for every 13 live births. Impassioned to improve outcomes, a dedicated team led by Dr. Dickens Onyango, a Medical Doctor and Public Health Researcher in Kisumu County, Kenya, recruited Quantiva Health to collaboratively embark on a transformative mission to make a difference.

An african women being helped by Quantiva Health's MIHIC score platform

In the imminent face of the myopia epidemic projected to impact half the global population by 2050 and the pervasive threat of Retinopathy of Prematurity (RoP) as a leading cause of preventable blindness in infants and children, one of the world’s leading eye care centers retained Quantiva Health to partner in groundbreaking endeavors equipping healthcare stakeholders with predictive insights into early signs of eye conditions.  With a remarkable track record of serving nearly 35 million people, this eye care center’s capacity to optimize vision health outcomes with Quantiva Health’s models spans from the most remote rural areas to bustling urban centers.

Eyes to the Future:  Charting a Course to Prevent Blindness and Myopia in Infants and Children

Quantiva Health’s eye care models are helping this world-class center forge a path forward where they can identify and intercept adverse outcomes, including preventing blindness in infants and mitigating myopia in children at a massive scale.  Quantiva’s models are yielding high accuracy and explainability.  When combined with the center’s expertise in clinical management, and their care structures designed to enable access for even the most rural and remote communities, we are collectively paving the way to help millions of children. Children worldwide continue to grapple with the elusive promise of healthy eyes, with consequential effects on their long-term health and well-being. Quantiva has emerged as a pioneering force, spearheading the use of AI and ML in the optimization and prevention of adverse eye health outcomes through early detection supporting strategic intervention.

A teenage girl with eye correction from LV Prasad Eye Institute

Sepsis exacts a devastating toll, claiming the lives of 11 million people annually. It stands as the foremost cause of hospital deaths, ranking third in the leading causes of mortality in the US. This life-threatening condition arises from infection-induced damage to the body's tissues and organs, often resulting in organ failure, amputation, disability, and death. Prevention and early treatment are vital to reducing sepsis fatalities. Addressing this critical issue, the Austere environments Consortium for Enhanced Sepsis Outcomes (ACESO), an international consortium dedicated to crafting tools and strategies for enhancing survival in severe infection cases, has forged a strategic partnership with Quantiva Health to confront this formidable challenge head-on.

Revolutionizing Patient Outcomes in Infectious Diseases and Impacts:  Predicting Survival in Suspected Sepsis Cases

"ACESO’s collaboration with Quantiva Health drives toward our mission of evidence-based clinical management for severe infections and sepsis in resource-limited settings across the globe. Using predictive models with host immune and physiological biomarkers along with clinical symptoms, Quantiva Health is working towards improving health outcomes for sepsis patients. This partnership bolsters ACESO's commitment to global health utilizing advanced data analytics, propelling us towards a future where AI/ML transforms patient outcomes worldwide and helps us better plan and prioritize resources for high-risk patients."


- Dr. Subramaniam Krishnan, Ph.D., Chief Science Strategist ACESO

Quantiva’s solutions include deep learning-based competing risk survival models for predicting sepsis outcomes and multi-state competing risk survival models for patients admitted in hospital settings with suspected sepsis. AI and systems biology can converge to help combat infectious diseases, particularly for vulnerable populations. Our work supports drug discovery, infection biology, diagnostics, and predictions of adverse outcomes at patient and population levels.

A female patient suffering from sepsis

Having spent the past decade developing a proprietary oral testosterone therapy to help millions suffering from testosterone deficiency, Marius Pharmaceuticals is paving the way for a new frontier in testosterone. Given that testosterone is central to overall health and well-being, Marius engaged Quantiva Health to perform a treatment benefit assessment of their novel drug over existing treatments for a large healthcare system.

Unlocking Holistic Health: Transforming Metabolic Wellness Through Innovative Pharmacoeconomics

"Quantiva Health has exhibited both hustle and commitment to evidence-driven analysis, economic modeling and deep research underscoring Value-Proposition of our oral testosterone capsule KYZATREX."

 

- Shalin Shah, CEO, Marius Pharmaceuticals

Quantiva’s expertise extends to pharmacoeconomics services, ensuring our clients benefit from a holistic perspective that quantifies therapy benefits and side effects to improve lives while maximizing economic value.

Healthy lifestyle of elderly patient
CognitiveCare Inc. is now doing business as Quantiva Health
bottom of page